PUBLISHER: Grand View Research | PRODUCT CODE: 1630924
PUBLISHER: Grand View Research | PRODUCT CODE: 1630924
The global non-invasive coronary imaging market size is expected to reach USD 596.8 million by 2030, registering a CAGR of 6.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Need to diagnose critical cardiac conditions in a short time span, increased deaths by coronary artery diseases, the growing geriatric population, and the growing need to avoid complications of invasive coronary imaging. Coronary artery disease is the leading cause of death in all regions across the globe. According to the Centers for Disease Control and Prevention, to date, 20.1 million adults have CAD. In 2020, 2 in every 10 geriatric patients above the age of 65, died due to CAD.
Non-invasive imaging has recently been utilized to assess the existence, severity, and prognosis of coronary artery disease as a result of advancements in imaging technology. The anatomical importance of coronary artery stenosis can be determined by stress myocardial perfusion imaging, such as SPECT/PET and stress MRI, whereas coronary CT angiography and MRI of the coronary arteries give anatomical assessments of coronary stenosis. Studies published in the National Center for Biotechnology Information (NCBI), stated that CT angiography showed promising results in the detection of CAD.
Its sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 94%, 83%, 48%, and 99%, respectively, to detect 70% stenosis. Thus, CT angiography shows promising results as a valuable tool for the diagnosis of significant coronary artery disease. Another research study published in NCBI shows promising results of noninvasive cardiac MR over echocardiography. The study compared dobutamine stress CMR (DSMR) with dobutamine stress echocardiography (DSE) in the detection of CAD (>=50% stenosis) using ICA as the gold standard. It resulted that, DSMR has higher diagnostic accuracy than that DSE in patients with suspected CAD.
The outbreak of the COVID-19 pandemic led to a decline in research activities, the closure of universities and academic institutions, and a decline in clinical trial activities. The fear of virus spread also declined any diagnostic or surgical activities at end-use settings. The economic crunch at hospitals, diagnostic centers, or clinics, led to the reduced adoption of software and systems for non-invasive diagnosis. Thus, the pandemic led to a decline in the market in 2020.